Phenylbutyrate in Proteinuric Nephropathies

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: 4-phenylbutyric acid

Criteria

Inclusion Criteria:

• Chronic Kidney disease for ore than 3 months

• Proteinuria > 1g/d or 0,1g/mmmol creatinine

• eGFR >30ml/mn/1,73m2

• written informed consent

• affiliated with social security health insurance

Exclusion Criteria:

• Women with childbearing potential

• Recent (<3 months) modification of ACE inhibitors or ARB

• Acute renal failure

• eGFR <30ml/mn/1,73m2

• Nephrotic syndrome (albuminélia <30g/l)

• Infection with HIV, HCV, HBV

• Liver insufficiency

• No affiliated with social security health insurance

• inclusion in another protocol of biomedical research

• risk of non-adherence to protocol and visits

• patients having a cardiac insufficiency of grade 3 or 4

• patient requiring of a strict salt-free diet

• patients under corticoids or immunosuppresseurs

• clinical intolerance in the treatment

• intolerance in the fructose, the syndrome of malabsorption glucose and galactose or a deficit in sucrase / isomaltase

• patients treated by Probenecide